<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236014</url>
  </required_header>
  <id_info>
    <org_study_id>114014</org_study_id>
    <nct_id>NCT01236014</nct_id>
  </id_info>
  <brief_title>Indirect Comparison Between Eltrombopag &amp; Romiplostim</brief_title>
  <official_title>Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An indirect comparison to compare the efficacy of eltrombopag versus romiplostim
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and
      romiplostim using placebo as a common comparator
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Durable response: platelet count of &gt;=50 and &lt;400 Gi/L</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response: either a durable response or a transient platelet response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Thrombocytopaenia</condition>
  <arm_group>
    <arm_group_label>Eltrombopag &amp; standard of care</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Romiplostim &amp; standard of care</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag &amp; standard of care</description>
    <arm_group_label>Eltrombopag &amp; standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <description>Romiplostim &amp; standard of care</description>
    <arm_group_label>Romiplostim &amp; standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo &amp; standard of care</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Identified through a systematic review: TRA102537, Kuter 2008
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with ITP

          -  Pre-specified treatment

          -  Prospective clinical studies with at least 10 patients

        Exclusion Criteria:

          -  Adults with ITP for other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 3, 2011</lastchanged_date>
  <firstreceived_date>November 4, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
